REFRACTORY LYMPHOMA
Clinical trials for REFRACTORY LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study looks at how well the drug glofitamab works in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are tracking how many patients achieve a complete response after receiving glofitamab through a compassionate use p…
Matched conditions: REFRACTORY LYMPHOMA
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New combo therapy shows promise for hard-to-treat childhood cancers
Disease control CompletedThis early-stage study tested a mix of two drugs (pembrolizumab and decitabine) plus targeted radiation in 22 children and young adults whose solid tumors or lymphoma had returned or stopped responding to treatment. The main goals were to see if the combination was safe and toler…
Matched conditions: REFRACTORY LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Weekly radiation may ease path to CAR t for tough lymphomas
Disease control CompletedThis study tested a new radiation schedule (once a week for 5 weeks) in 10 people with B-cell lymphoma that came back or didn't respond to treatment. The goal was to see if this schedule is practical and reduces side effects before patients receive CAR T-cell therapy. The approac…
Matched conditions: REFRACTORY LYMPHOMA
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC